Terug
32
Dagbereik
€ 15,35
€ 15,35
52-Weeksbereik
€ 9,01
€ 15,47
Volume
100
50D / 200D Gem.
€ 14,96
/
€ 12,80
Vorige Slotkoers
€ 15,47
Koershistorie
Financiële Trends
Sectorvergelijking
vs Healthcare sector mediaan (626 peers)
| Metriek | Aandeel | Sector Mediaan |
|---|---|---|
| P/E | 71,3 | 0,4 |
| P/B | 2,2 | 2,9 |
| ROE % | 3,1 | 3,8 |
| Net Margin % | 4,2 | 3,9 |
| Rev Growth 5Y % | 7,6 | 10,0 |
| D/E | 0,2 | 0,2 |
Belangrijkste Punten
Revenue grew 7,57% annually over 5 years — modest growth
Earnings grew 355,14% over the past year
ROE of 3,10% is below average
Debt/Equity of 0,23 — conservative balance sheet
Generating 134,24M in free cash flow
P/E of 71,34 — premium valuation
Groei
Revenue Growth (5Y)
7,57%
Revenue (1Y)12,37%
Earnings (1Y)355,14%
FCF Growth (3Y)N/A
Kwaliteit
Return on Equity
3,10%
ROIC2,77%
Net Margin4,17%
Op. Margin6,11%
Veiligheid
Debt / Equity
0,23
Current Ratio2,04
Interest Coverage3,79
Waardering
P/E Ratio
71,34
P/B Ratio2,22
EV/EBITDA48,75
Dividend Yield0,01%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 12,37% | Revenue Growth (3Y) | 11,28% |
| Earnings Growth (1Y) | 355,14% | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | 7,57% | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | 1,11B | Net Income (TTM) | 46,18M |
| ROE | 3,10% | ROA | 1,98% |
| Gross Margin | 41,21% | Operating Margin | 6,11% |
| Net Margin | 4,17% | Free Cash Flow (TTM) | 134,24M |
| ROIC | 2,77% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | 0,23 | Current Ratio | 2,04 |
| Interest Coverage | 3,79 | Dividend Yield | 0,01% |
| Valuation | |||
| P/E Ratio | 71,34 | P/B Ratio | 2,22 |
| P/S Ratio | 2,97 | PEG Ratio | 0,16 |
| EV/EBITDA | 48,75 | Dividend Yield | 0,01% |
| Market Cap | 3,29B | Enterprise Value | 3,30B |
Income Statement
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 1,11B | 985,72M | 894,52M | 863,25M | 827,20M |
| Net Income | 46,18M | 10,15M | -38,47M | 4,28M | -40,86M |
| EPS (Diluted) | 0,21 | 0,05 | -0,20 | 0,02 | -0,23 |
| Gross Profit | 456,47M | 767,68M | 682,04M | 680,78M | 655,61M |
| Operating Income | 67,69M | 36,09M | -5,26M | 46,87M | 5,75M |
Balance Sheet
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 2,34B | 2,40B | 2,37B | 2,15B | 2,14B |
| Total Liabilities | 829,43M | 908,28M | 911,59M | 828,98M | 855,71M |
| Shareholders' Equity | 1,49B | 1,49B | 1,46B | 1,32B | 1,29B |
| Total Debt | 342,86M | 408,81M | 403,25M | 403,88M | 396,11M |
| Cash & Equivalents | 337,64M | 377,10M | 387,95M | 248,38M | 206,49M |
| Current Assets | 713,72M | 741,14M | 718,66M | 552,72M | 499,27M |
| Current Liabilities | 350,51M | 353,42M | 351,08M | 274,61M | 280,99M |
Strategiescores
This stock passed the criteria for 1 strategy
Score = fit strength (0–100)
Rank = position among all matches
Custom
Cash Flow Compounder
#778 of 1024
Recente Activiteit
Ingestapt
Cash Flow Compounder
Mar 24, 2026